

1 **The *Pseudomonas aeruginosa* lectin LecB causes integrin**
2 **internalization to facilitate crawling of bacteria underneath host cells**

3

4 Running title: **Integrin internalization by the lectin LecB**

5

6 *Roland Thuenauer^{a,b,c,d,#}, Alessia Landi^{a,b}, Anne Trefzer^{a,b}, Silke Altmann^{a,b}, Sarah*
7 *Wehrum^{a,b}, Thorsten Eierhoff^{a,b}, Britta Diedrich^e, Jörn Dengjel^e, Alexander Nyström^f,*
8 *Anne Imberty^g, Winfried Römer^{a,b,#}*

9

10 ^a Faculty of Biology, Albert-Ludwigs-University Freiburg, Freiburg, Germany

11 ^b BIOS Centre for Biological Signalling Studies, Albert-Ludwigs-University
12 Freiburg, Freiburg, Germany

13 ^c Advanced Light and Fluorescence Microscopy Facility, Centre for Structural
14 Systems Biology (CSSB), Hamburg, Germany

15 ^d Department of Biology, University of Hamburg, Hamburg, Germany

16 ^e Department of Biology, University of Fribourg, Fribourg, Switzerland; and
17 Department of Dermatology, Medical Center - Albert-Ludwigs-University Freiburg,
18 Freiburg, Germany

19 ^f Department of Dermatology, Medical Center - Albert-Ludwigs-University Freiburg,
20 Freiburg, Germany

21 ^g Univ. Grenoble Alpes, CNRS, CERMAV, Grenoble, France

22

23 [#] Correspondence to Winfried Römer (winfried.roemer@bioss.uni-freiburg.de,
24 Schänzlestraße 18, Albert-Ludwigs-University Freiburg, 79104 Freiburg, Germany)

25 or Roland Thuenauer (roland.thuenauer@cssb-hamburg.de, Notkestraße 85, CSSB c/o

26 DESY, 22607 Hamburg, Germany).

27

28 **Abstract**

29 The opportunistic bacterium *Pseudomonas aeruginosa* produces the fucose-specific
30 lectin LecB, which has been identified as virulence factor. LecB has a tetrameric
31 structure with four opposing binding sites and has been shown to act as crosslinker.
32 Here, we demonstrate that LecB strongly binds to the glycosylated moieties of β 1-
33 integrins on the basolateral plasma membrane of epithelial cells and caused rapid
34 integrin endocytosis. Whereas internalized integrins were degraded via a lysosomal
35 pathway, washout of LecB restored integrin cell surface localization, thus indicating a
36 specific and direct action of LecB on integrins to bring about their endocytosis.
37 Interestingly, LecB was able to trigger uptake of active and inactive β 1-integrins and
38 also of complete α 3 β 1-integrin - laminin complexes. We provide a mechanistic
39 explanation for this unique endocytic process by showing that LecB has the additional
40 ability to recognize fucose-bearing glycosphingolipids and caused the formation of
41 membrane invaginations on giant unilamellar vesicles. In cells, LecB recruited
42 integrins to these invaginations by crosslinking integrins and glycosphingolipids. In
43 epithelial wound healing assays, LecB specifically cleared integrins from the surface
44 of cells located at the wound edge and blocked cell migration and wound healing in a
45 dose-dependent manner. Moreover, the wild type *P. aeruginosa* strain PAO1 was able
46 to loosen cell-substrate adhesion in order to crawl underneath exposed cells, whereas
47 knockout of LecB significantly reduced crawling events. Based on these results we
48 suggest that LecB has a role in disseminating bacteria along the cell - basement
49 membrane interface.

50 **Importance**

51 *Pseudomonas aeruginosa* is a ubiquitous environmental bacterium that is one of the
52 leading causes for nosocomial infections. *P. aeruginosa* is able to switch between
53 planktonic, intracellular, and biofilm-based lifestyles, which allows it to evade the
54 immune system as well as antibiotic treatment. Hence, alternatives to antibiotic
55 treatment are urgently required to combat *P. aeruginosa* infections. Lectins, like the
56 fucose-specific LecB, are promising targets, because removal of LecB resulted in
57 decreased virulence in mouse models. Currently, several research groups are
58 developing LecB inhibitors. However, the role of LecB in host-pathogen interaction is
59 not well understood. The significance of our research is in identifying cellular
60 mechanisms how LecB facilitates *P. aeruginosa* infection: We introduce LecB as new
61 member to the list of bacterial molecules that bind integrins and show that *P.*
62 *aeruginosa* can efficiently move forward underneath attached epithelial cells by
63 loosening cell - basement membrane attachment in a LecB-dependent manner.

64 **1 Introduction**

65 *Pseudomonas aeruginosa* is a ubiquitous Gram-negative environmental bacterium. For
66 humans it acts as an opportunistic pathogen and can cause severe infections,
67 predominantly in cystic fibrosis patients (1) and immunocompromised individuals,
68 such as HIV patients (2), patients receiving cancer treatment (3), patients with assisted
69 ventilation (4), and patients with burn wounds (5). *P. aeruginosa* infections are
70 difficult-to-treat because the bacterium has a high natural resistance to antibiotics and
71 rapidly acquires new antibiotic resistances (6). In fact, several outbreaks caused by
72 multidrug-resistant *P. aeruginosa* strains were recently reported (7, 8). In addition, the
73 bacterium is able to adopt various lifestyles that allow it to evade the immune system
74 as well as antibiotic treatment. In particular, *P. aeruginosa* can form biofilms (9) and
75 invades and proliferates in host cells (10). These properties make *P. aeruginosa* an
76 imminent threat for global health and therefore the World Health Organization (WHO)
77 categorized *P. aeruginosa* with ‘Priority 1’ on its recently released ‘WHO priority
78 pathogens list for research and development of new antibiotics’ (11), which highlights
79 the need to develop novel treatment strategies for *P. aeruginosa* infections (12).

80

81 When infecting the human body, *P. aeruginosa* typically encounters polarized
82 epithelial cell layers, which function as protective barriers (10). As an opportunistic
83 bacterium, *P. aeruginosa* adapts its strategy according to the circumstances it
84 encounters. It harnesses weak spots, for example sites where cells divide or are
85 extruded, to proceed to the basolateral side of epithelia (13). *P. aeruginosa* has also
86 been shown to have a propensity to enter and colonize wounded epithelia (10), and
87 there is ample experimental evidence that loss of epithelial polarity increases
88 detrimental effects of *P. aeruginosa* on host cells (10). In addition, *P. aeruginosa* has

89 evolved strategies to manipulate the polarity of host epithelial cells to facilitate
90 infection (10, 14). When reaching the basolateral side, *P. aeruginosa* gets access to
91 integrins, which are typically restricted to the basolateral plasma membrane of
92 epithelial cells. Although integrins are well known as receptors for multiple pathogens
93 (15–17), and previous studies have shown that *P. aeruginosa* is able to bind to $\alpha 5\beta 1$ -
94 integrins in nasal epithelial cells (18) and to $\alpha \nu \beta 5$ -integrins in lung epithelial cells (19),
95 the specific roles for integrins for *P. aeruginosa* infection remain unclear.

96
97 *P. aeruginosa* produces two carbohydrate-binding proteins, so-called lectins,
98 LecA and LecB, which are also named PA-IL and PA-IIL, respectively (20). Whereas
99 LecA is galactophilic, LecB prefers fucose (20). LecB is transported to the outer
100 bacterial membrane, where it binds to the porin OprF, resulting in its presentation at
101 the outer surface of *P. aeruginosa* (21, 22). Several lines of evidence indicate that LecB
102 is an important virulence factor. LecB-deficient *P. aeruginosa* are less pathogenic (23)
103 and show diminished biofilm formation (21). In addition, LecB was found to abrogate
104 ciliary beating in human airways (24) and to diminish tissue repair processes in lung
105 epithelia (25). These findings raised the prospect to establish alternative treatment
106 strategies for *P. aeruginosa* infections by blocking LecB, and stimulated ongoing
107 efforts of several research groups to develop LecB inhibitors (26–31).

108
109 However, the functions of LecB remain difficult to pin down, because as a lectin
110 it can bind to many different host cell receptors. Here, we demonstrate that integrins
111 are major receptors of LecB. Moreover, we observed that LecB binding to integrins
112 resulted in their rapid cellular uptake together with their basement membrane ligands.
113 We provide a mechanistic explanation for this distinctive endocytosis process by

114 showing that LecB binding to fucose-bearing lipids induces membrane invaginations
115 and, furthermore, LecB positions integrins in these invaginations by crosslinking
116 integrins and lipids. As functional consequence, purified LecB caused inhibition of cell
117 migration and abrogation of epithelial wound healing by specifically internalizing
118 exposed integrins in cells at the wound edge. Furthermore, we could demonstrate that
119 the wild type (wt) *P. aeruginosa* strain PAO1 is able to locally disturb cell adhesion
120 and to crawl underneath epithelial cells. Importantly, knocking out LecB diminished
121 the number of *P. aeruginosa* found underneath epithelial cells, thus implicating LecB
122 as virulence factor enabling bacteria to colonize host tissue along the interface between
123 cells and the basement membrane.

124 **2 Results**

125 *2.1 Differential effects of LecB at the apical and basolateral side of polarized epithelial*
126 *cells*

127 When *P. aeruginosa* infects a human body, it typically encounters first the apical pole
128 of epithelial cells. Through induced or pre-existing damages, the bacterium can access
129 the basolateral cell pole of epithelial cells. Since the apical and basolateral plasma
130 membrane of individual epithelial cells harbors distinct sets of membrane proteins and
131 lipids, we investigated if LecB causes different effects when applied to the apical or
132 basolateral side. We chose Madin-Darby canine kidney (MDCK) cells as model system
133 because they reliably form polarized monolayers *in vitro* (32, 33) and have been already
134 successfully used in *P. aeruginosa* infection studies (14, 34). Purified LecB was able
135 to bind apical and basolateral plasma membranes of MDCK cells (Fig. S1A).
136 Interestingly, apical application of LecB resulted in completely different responses of
137 the host cells than basolateral application (Fig. 1A). After 6 h and 12 h of apical
138 treatment with 50 $\mu\text{g/ml}$ (4.3 μM) LecB the overall morphology of the cells was intact
139 as evidenced by staining of β -catenin (red) that remained basolateral and GPI-GFP
140 (green) that remained apical. In addition, tight junction integrity was not disturbed as
141 demonstrated by the unchanged staining of ZO-1 (white in Fig. 1A) and the preserved
142 trans-epithelial electrical resistance (TEER; Fig. 1B). In contrast, 6 h and 12 h of
143 basolateral treatment with 50 $\mu\text{g/ml}$ LecB resulted in rounded cell morphologies and
144 severely disturbed epithelial polarity. GPI-GFP became localized all around the cells
145 and tight junctions almost disappeared (Fig. 1A), which was corroborated by a drastic
146 reduction of the TEER (Fig. 1B). Importantly, these effects cannot be explained by
147 potential LecB-mediated apoptosis or necrosis (Fig. S1B-C). Yet, the observed
148 consequences seem to be specific for LecB, because another fucose-binding lectin, *Ulex*

149 *europaeus* agglutinin I (UEA-I (35)), which did also bind to apical and basolateral
150 plasma membranes of MDCK cells (Fig. S1D), did not cause apparent changes in cell
151 morphology (Fig. S1E), nor did it influence the TEER (Fig. S1F).

152 Taken together, basolateral application of LecB dissolves epithelial polarity in MDCK
153 cells, whereas another fucose-binding lectin, UEA-I, does not cause such effects.

154

155 *2.2 Basolaterally applied LecB binds β 1-integrin and causes its internalization*

156 To uncover the mechanisms of LecB-induced loss of epithelial polarity, we monitored
157 the localization of cell adhesion receptors upon basolateral LecB stimulation. This
158 revealed a rapid and efficient internalization of β 1-integrins (Fig. 1C). Interestingly,
159 this effect was reversible after washout of LecB after 6 h (Fig. 1D), and the timing of
160 β 1-integrin internalization and return to the cell surface correlated well with decrease
161 and increase of the TEER (Fig. 1E).

162 To elucidate LecB-triggered β 1-integrin internalization, we first investigated if LecB
163 binds to β 1-integrin. To this end we used LecB-biotin to precipitate LecB-receptor
164 complexes with streptavidin beads. Western blot analysis of the precipitates showed
165 that LecB-biotin is able to bind to β 1-integrins only when applied to the basolateral side
166 (Fig. 2A). The binding of LecB-biotin to β 1-integrin appeared to be strong, since LecB-
167 biotin was able to extract approximately 75% of total β 1-integrin when applied to the
168 basolateral side, as quantified from the band intensities of the Western blot. In addition,
169 fluorescently labeled LecB co-localized with internalized β 1-integrins (Fig. 2B) and
170 was able to bind immunoprecipitated β 1-integrin in a far-Western assay in dependence
171 of the β 1-integrin glycosylation status (Fig. 2C), which provides complementary
172 evidence for the capacity of LecB to bind to glycosylated β 1-integrin.

173 In summary, LecB recognizes β 1-integrin at the basolateral cell surface and causes its
174 rapid internalization.

175

176 *2.3 α 3-integrin and laminin are also internalized and degraded upon basolateral LecB*
177 *application*

178 From the far-Western assay in Fig. 2C it can be seen that LecB recognized not only
179 glycosylated β 1-integrin, but also other receptors that were presumably co-precipitated
180 during β 1-integrin immunoprecipitation (blue arrows). Hence, in a next step we
181 identified basolateral interaction partners of LecB by LecB-biotin co-precipitation
182 followed by mass spectrometry analysis and found 65 profoundly enriched proteins
183 (Table S1). This analysis revealed that LecB is able to pull down virtually all integrins
184 expressed by MDCK cells (36), and also many proteins known to interact with
185 integrins, such as tetraspanins, basigin, EGFR, were detected. From this it appears that
186 integrins are major cellular receptors of LecB. We focused our further analysis on α 3 β 1-
187 integrin and were able to demonstrate that α 3-integrins are co-internalized with β 1-
188 integrins upon basolateral LecB application (Fig. 3A). Surprisingly, also the major
189 ligands of α 3 β 1-integrin expressed by MDCK cells, laminin-332 and/or -511 (37), were
190 co-internalized (Fig. 3B). This suggests that LecB is able to cause endocytosis of intact
191 α 3 β 1-integrin – laminin complexes. To measure the dynamics of α 3 β 1-integrin
192 internalization we carried out surface biotinylation experiments (38). These
193 experiments confirmed the rapid LecB-triggered internalization of α 3- and β 1-integrin
194 subunits (Figs. 3C - 3E). In addition, the surface biotinylation experiments revealed that
195 also the intracellular amount of α 3- and β 1-integrin subunits decreased upon LecB
196 stimulation, suggesting a degradation of internalized integrins. Consistently, LecB-
197 mediated reduction of integrins was also detected when whole cell lysates were

198 subjected to Western blot analysis (Fig. S2A). Loss of integrins by degradation is
199 further supported by our finding that internalized integrins after basolateral LecB
200 treatment showed a time-dependent increase in co-localization with the late endosome
201 marker Rab9 (Figs. S2B-C) and the lysosome marker Lamp1 (Figs. S2D-E).
202 In the surface biotinylation experiments we were not able to distinguish between active
203 and inactive β 1-integrins. Thus, we devised an alternative strategy in which we applied
204 activation-specific β 1-integrin antibodies to the basolateral surface of live cells. This
205 approach revealed that LecB internalizes active and inactive β 1-integrins at similar
206 kinetics (Figs. 3F – 3H and Fig. S3F), which indicates that the activation status of β 1-
207 integrins does not play an important role in LecB-mediated integrin internalization.
208 Taken together, LecB binds integrins, including α 3 β 1-integrin, and causes their
209 internalization and degradation regardless of their activation status and bound basement
210 membrane ligands.

211

212 *2.4 Membrane invagination by LecB and LecB-mediated crosslinking of fucosylated* 213 *lipids with β 1-integrin can explain LecB-triggered integrin internalization*

214 Endogenous lectins, like galectin-3, were previously shown to be able to mediate
215 integrin internalization (39, 40). The proposed mechanism for galectin-3-mediated
216 integrin internalization is that galectin-3 is able to cause plasma membrane
217 invaginations by binding to glycolipids and also drags integrins into the invaginated
218 membrane regions by functioning as a crosslinker between glycolipids and integrins.
219 Since LecB is a tetramer with four opposing fucose binding sites (41), which represents
220 an ideal geometry for a potential crosslinker, we investigated if a galectin-like
221 mechanism could explain LecB-mediated β 1-integrin internalization.

222 In a first step we examined if binding of LecB to fucosylated glycosphingolipids is
223 sufficient to induce membrane invaginations in giant unilamellar vesicles (GUVs) (42).
224 Indeed, GUVs containing glycosphingolipids that bear the fucosylated Lewis a antigen
225 (Fig. 4A) or other fucosylated glycosphingolipids (Fig. S3) showed invaginations
226 immediately after LecB application, whereas control GUVs with the non-fucosylated
227 glycosphingolipid lactotetraosylceramide (Lc4cer) did not (Fig. 4A). To investigate the
228 relevance of this effect, we carried out experiments with energy-depleted cells, because
229 under these conditions cellular machineries cannot pinch off vesicles, which previously
230 led to well-visible membrane invaginations when other lipid-binding lectins like Shiga
231 toxin were applied (42, 43). Indeed, LecB was able to induce plasma membrane
232 invaginations in energy-depleted MDCK cells (Fig. 4B). Importantly, β 1-integrin co-
233 localized with fluorescently labeled LecB at invaginations (Fig. 4B, magnification),
234 thus implicating that LecB can recruit integrins to invaginations. Furthermore, we
235 observed that basolateral LecB application led to marked clustering of endogenous
236 galectin-3 (Fig. S4), which could suggest that LecB outcompetes galectin-3-integrin
237 interaction.

238 In summary, LecB is able to cause membrane invaginations upon binding to fucose-
239 bearing glycosphingolipids. Since LecB is also able to bind integrins and thus to
240 crosslink lipids in membrane invaginations with integrins, this provides a mechanistic
241 explanation for LecB-mediated integrin internalization.

242

243 *2.5 LecB inhibits cell migration and epithelial wound healing*

244 As an opportunistic pathogen *P. aeruginosa* mainly relies on, and exploits, extrinsic
245 circumstances – like a wound – to gain access to the basolateral side of epithelia. In
246 addition, integrin blocking, e.g. through antibodies, has been previously shown to

247 inhibit cell migration in wound healing assays (44). These considerations motivated us
248 to investigate the effect of LecB on epithelial wound healing. Indeed, presence of LecB
249 strongly inhibited collective cell migration and wound healing in MDCK monolayers
250 (Fig. 5A). Importantly, this effect was blockable with L-fucose, demonstrating that
251 LecB needs to bind to host cells to cause migration defects. Moreover, we established
252 that the blockage of wound healing by LecB occurred in a dose-dependent manner, with
253 concentrations larger than 50 $\mu\text{g/ml}$ completely blocking cell migration (Figs. 5B and
254 5C), whereas another fucose-binding lectin, UEA-I (50 $\mu\text{g/ml}$), did not induce
255 suppression of wound healing (Fig. S5A). The inhibitory effect of LecB on wound
256 healing was – as other LecB-mediated effects before – reversible by washing out LecB
257 (Fig. S5B).

258 To explain the abrogation of cell migration by LecB we carried out live cell imaging
259 experiments with MDCK cells stably expressing the plasma membrane marker ML-
260 GFP (45). ML-GFP allowed visualizing lamellipodia formed by migrating MDCK cells
261 (Fig. 5D, ctrl, white arrows). Interestingly, when cells were treated with LecB right
262 after wounding, no lamellipodia formed (Fig. 5D, LecB), whereas washout of LecB
263 was sufficient to reinstate lamellipodia formation and cell migration (Fig. S5C). When
264 migrating cells were treated with LecB, lamellipodia ‘froze’ and LecB strongly bound
265 to lamellipodia (Fig. S6). It is also interesting to note that cells deeper within the
266 monolayer, which expose only their apical membranes to LecB in this assay, did still
267 move (Fig. S6). In subsequent experiments we stained for $\beta 1$ -integrins in wound
268 healing assays. This revealed that cells at the wound edge take up large amounts of
269 LecB and in the same cells pronounced $\beta 1$ -integrin internalization was evident (Fig. 5E,
270 white arrows), which can explain why these cells are not able to migrate any more.

271 Taken together, LecB inhibits epithelial wound healing in a reversible manner, which
272 is presumably caused by the fact that integrins in wound edge cells are accessible by
273 LecB and are internalized.

274

275 *2.6 In dependence of LecB expression, P. aeruginosa is able to crawl underneath cells*

276 The additional and probably dominant cytotoxic effects caused by the numerous toxins
277 produced by *P. aeruginosa* prevented us from directly quantifying an effect of LecB
278 knockdown in *in vitro* wound healing assays with live *P. aeruginosa*. However, we
279 observed that *P. aeruginosa* (PAO1-wt) is able to crawl underneath exposed cells (Fig.
280 6A). We postulated that this requires at least local loosening of potentially integrin-
281 mediated cell-substrate adhesion. We tested this hypothesis by investigating the
282 influence of LecB on '*P. aeruginosa*-crawling'. To this end, we used a LecB-deficient
283 PAO1 strain (PAO1-dLecB), which exhibited the same growth kinetics as PAO1-wt
284 (Fig. S7A). After overnight culture the PAO1-wt strain showed clear expression of
285 LecB, whereas the LecB-deficient *P. aeruginosa* (PAO1-dLecB) did not (Figs. S7B
286 and S7C). In accordance with our hypothesis, PAO1-dLecB was visibly found less
287 underneath cells (Fig. 6A). To substantiate the experimental procedure, we established
288 that increasing the multiplicity of infection (MOI) (Figs. 6B and 6C) and increasing the
289 duration of incubation (Figs. 6B and 6D) also increased the number of bacteria crawling
290 underneath cells. Importantly, for all investigated conditions, the number of
291 underneath-crawling bacteria per cell was lower for the PAO1-dLecB strain in
292 comparison to the PAO1-wt strain.

293 In summary, our study reveals a novel mechanism in which LecB, through impairing
294 cell-to-basement membrane attachment, allows for the creation of microniches
295 enabling sub-epithelial colonization by *P. aeruginosa*.

296 **3 Discussion**

297 *3.1 Integrins are major receptors of LecB*

298 Lectins bind to carbohydrates and can therefore have multiple receptors that express
299 the appropriate glycosylation. Hence it is interesting that our experiments suggest a
300 favored binding of LecB to integrins. LecB binding to β 1-integrin appeared to be
301 strong, because LecB was able to recover 75% of total β 1-integrin from cells when it
302 was basolaterally applied and had only access to β 1-integrin at the cell surface.. As
303 expected, LecB binding to β 1-integrin solely occurred through carbohydrates, since
304 removal of β 1-integrin glycosylation abolished binding. Furthermore, mass
305 spectrometry analysis of all basolateral LecB receptors revealed that virtually all
306 integrins expressed by MDCK cells were among the top hits, including many integrin-
307 associated proteins that were presumably recovered through co-precipitation with
308 integrins.

309 This introduces LecB as new member to the list of bacterial molecules that bind
310 integrins.

311

312 Another fucose binding lectin, UEA-I, was not able to mount any of the cellular effects
313 that LecB caused. This shows that only binding to fucose is not sufficient and suggests
314 that LecB has additional features that bring about its specific capabilities. First, LecB
315 and UEA-I prefer different fucose linkages in oligosaccharides (UEA-I binds α _{1,2}-
316 linked fucose but only weakly to α _{1,3}- and α _{1,6}-linked fucose (46, 47); LecB shows a
317 slight preference for α _{1,4}-linked fucose, but also binds to α _{1,2}- and α _{1,3}-linked fucose
318 (48–50)). In addition, LecB is a tetramer with four fucose binding sites, but UEA-1 is
319 a dimer offering only two binding sites (35).

320 It is also worth to note that the sequence of LecB varies slightly between different
321 strains of *P. aeruginosa* (51, 52). Since ligand binding among LecB variants is
322 conserved, we expect that these LecB variants are utilized in similar ways as we
323 reported here for LecB in the *P. aeruginosa* strain PAO1.

324

325 *3.2 Mechanism of LecB-mediated integrin internalization*

326 Since LecB recognizes only the carbohydrate moieties of integrins, it is able to
327 manipulate integrins via unique mechanisms. The structure of LecB with four opposing
328 binding sites is ideal to crosslink receptors. This has been demonstrated before *in vitro*
329 by showing that LecB is able to crosslink GUVs that contain LecB receptors (53).

330 We hypothesize that the crosslinking capacity of LecB is key for the observed rapid
331 internalization of integrins. In addition to integrins, LecB was also able to recognize
332 fucose-bearing glycosphingolipids and to cause membrane invaginations without the
333 need of additional energy input, which replicates effects caused by other
334 glycosphingolipid-binding lectins like StxB (42), CtxB (54), or RSL (55). In addition,
335 β 1-integrin was also found on LecB-generated membrane invaginations on energy-
336 depleted cells. This suggests that LecB causes on the one hand membrane invaginations
337 and on the other hand is able to recruit integrins to these invaginations, thus constituting
338 a potent endocytic mechanism. A similar mechanism was suggested for the host cell-
339 endogenous protein galectin-3 (40). This means that bacteria have evolved molecules
340 like LecB that can hijack this endogenous uptake route. Importantly, LecB-mediated
341 lipid-integrin-crosslinking for internalization represents a mechanism that can explain
342 the observed integrin internalization that occurred regardless of integrin activation
343 status and carried also basement membrane ligands like laminins with it.

344

345 *3.3 LecB-triggered inhibition of wound healing*

346 LecB binding to basolateral cell surfaces caused cellular effects that could be causally
347 linked to integrin internalization. In fully polarized epithelial cells, binding of LecB to
348 basolateral cell surfaces, but not to apical cell surfaces, which do not contain significant
349 amounts of integrins, led to loss of apico-basal polarity. This indicates the need of
350 integrin internalization for dissolution of polarity. In addition, loss of polarity was
351 reversible after washout of LecB and coincided well with the return of β 1-integrin to
352 the basolateral plasma membrane.

353 Our data also suggest that LecB-mediated integrin internalization is responsible for the
354 observed block in cell migration in epithelial wound healing assays. First, integrins
355 were preferentially internalized in wound edge cells and LecB prominently bound to
356 lamellipodia in edge cells. This makes sense, since edge cells offer more cellular
357 surface area for LecB binding and expose their integrins in contrast to cells deeper
358 within the intact monolayer, which display only their apical surfaces to LecB. Second,
359 edge cells rapidly and efficiently stopped moving upon LecB treatment, whereas other
360 cells deeper within the monolayer preserved their capacity to move within the
361 monolayer.

362 Diminished healing of *P. aeruginosa*-infected wounds was reported previously (10).
363 However, *P. aeruginosa* possesses multiple mechanisms to manipulate and to
364 intoxicate host cells. We therefore anticipate that, in order to inhibit wound healing, *P.*
365 *aeruginosa* will apply different combinations of its arsenal, including LecB-mediated
366 inhibition of cell migration, in dependence of the host tissue (25).

367

368 *3.4 LecB has a role in enabling bacteria to crawl underneath host cells*

369 Our experiments revealed a novel feature of *P. aeruginosa* behavior: We observed that
370 bacteria frequently crawled underneath host cells. For this, at least local loosening of
371 cell-substrate adhesion is required, which could be achieved by LecB-mediated integrin
372 internalization. We therefore investigated the contribution of LecB to underneath-cell-
373 crawling of the *P. aeruginosa* strain PAO1. Indeed, knocking out LecB significantly
374 decreased crawling events. Based on our results, we suggest that *P. aeruginosa* uses
375 LecB to manipulate integrin-basement membrane interaction to proceed along the
376 interface between epithelial cells and the basement membrane.

377

378 In summary, our work brings integrins into focus as target of *P. aeruginosa* and
379 provides additional rationales for the ongoing efforts to develop LecB inhibitors as
380 additional treatment strategy to antibiotics (26–31).

381 **4 Materials and Methods**

382 *4.1 Antibodies, plasmids and reagents*

383 Used antibodies are listed in Table S2. The plasmid pPH-Akt-GFP encoding PH-Akt -
384 GFP was a gift from Tamas Balla (Addgene plasmid # 51465). The plasmid encoding
385 GFP tagged with a glycosylphosphatidylinositol (GPI) anchor (pGPI-GFP) was
386 described before (56). The plasmid encoding for GFP tagged with a Lyn-derived
387 myristoylation motif (pML-GFP) was a gift from Christian Wunder (Curie Institute,
388 Paris, France).

389 Recombinant LecB was produced in *Escherichia coli* BL21(DE3) cells and purified
390 with affinity columns as previously described (41). LecB and fluorophore-conjugated
391 LecB were used at a concentration of 50 µg/ml (4.3 µM) unless stated otherwise. UEA-
392 I and UEA-I-FITC were from Vector Labs. Cycloheximide, and L-fucose (6-Deoxy-L-
393 galactose) were from Sigma Aldrich.

394

395 *4.2 Mammalian cell culture, creation of stable cell lines*

396 MDCK strain II cells were cultured in Dulbecco's Modified Eagle's Medium (DMEM)
397 supplemented with 5% fetal calf serum (FCS) at 37 °C and 5% CO₂. Unless stated
398 otherwise 3×10⁵ MDCK cells were seeded per transwell filter (0.4 µm pore size,
399 polycarbonate membrane, #3401 from Corning) and cultured for 4 d before
400 experiments. For the creation of stable MDCK cell lines plasmids encoding the proteins
401 of interest and G418 resistance (pPH-Akt-GFP, pML-GFP, and pGPI-GFP) were
402 transfected into cells with Lipofectamine 2000 (Thermo Fisher). After allowing the
403 cells to express the proteins overnight, they were trypsinized and plated sparsely in
404 medium containing 1 mg/ml G418. After single colonies had formed, GFP-positive
405 colonies were extracted with cloning rings. At least 6 colonies were extracted for each

406 cell line, grown on transwell filters for 4 d, fixed and stained against the basolateral
407 marker protein β -catenin and the tight junction marker protein ZO-1 to assay their
408 polarized morphology. Based on these results we chose one colony for each cell line
409 for further experiments. TEER measurements were carried out using an EVOM2
410 equipped with chopstick electrodes (World Precision Instruments).

411

412 *4.3 Immunofluorescence*

413 Cells were washed two times with phosphate-buffered saline without Ca^{2+} and Mg^{2+}
414 (PBS), and then fixed with 4% (w/v) formaldehyde (FA) for 15 min at room
415 temperature. Samples were treated with 50 mM ammonium chloride for 5 min to
416 quench FA and then permeabilized with a SAPO medium (PBS supplemented with
417 0.2% (w/v) bovine serum albumin and 0.02% (w/v) saponin) for 30 min. Primary
418 antibodies were diluted in SAPO medium and applied on the samples for 60 min at
419 room temperature. After three washes with PBS, secondary dye-labeled antibodies,
420 and, if required, DAPI and dye-labeled phalloidin, were diluted in SAPO medium and
421 applied to the cells for 30 min at room temperature (details for the used antibodies are
422 listed in Table S2). After 5 washes with PBS cells were mounted for microscopy. Since
423 α 3-integrin antibodies did not work in FA-fixed cells, methanol fixation was applied in
424 this case. Briefly, cells were incubated with pre-cooled methanol for 15 min at $-20\text{ }^{\circ}\text{C}$.
425 After washing with PBS, cells were permeabilized with 0.05% (v/v) Triton X-100 for
426 10 min at room temperature and blocked with 3% (w/v) bovine serum albumin (BSA)
427 for 1 h at room temperature. Staining with primary and secondary antibodies was then
428 carried out as described before, but with a 3% (w/v) BSA solution.

429

430 *4.4 Microscopic imaging of fixed cells and live cell experiments*

431 For microscopic imaging an A1R confocal microscope (Nikon) equipped with a 60x
432 oil immersion objective (NA = 1.49) and laser lines at 405 nm, 488 nm, 561 nm, and
433 641 nm was utilized. Image acquisition and analysis was performed with NIS-Elements
434 4.10.04 (Nikon).

435 Live cell experiments were carried out at 37°C and MDCK cells grown as polarized
436 monolayers for 3 d on Lab-Tek II chambered cover glasses (8 well, 1.5 borosilicate
437 glass) were used. The medium was changed to recording medium (Hank's balanced salt
438 solution (HBSS) supplemented with 1% FCS, 4.5 g/L glucose, and 20 mM HEPES).

439

440 *4.5 Wound healing assays*

441 MDCK cells were seeded on 12 well plates or, for live cell microscopy of cell
442 migration, on 8 well Lab-Tek II chambered cover glasses and allowed to form confluent
443 monolayers for 3 d. Then cells were scratched with a 200 µl-pipet tip to inflict a wound.
444 On 12 well plates, marker lines were drawn on the bottom to ensure that always the
445 same position of the wound was imaged.

446

447 *4.6 Western blot analysis*

448 Cells were washed twice with PBS and lysed in RIPA buffer (20 mM Tris (pH 8), 0.1%
449 (w/v) SDS, 10% (v/v) glycerol, 13.7 mM NaCl, 2mM EDTA, and 0.5% (w/v) sodium
450 deoxycholate in water), supplemented with protease inhibitors (0.8 µM aprotinin, 11
451 µM leupeptin, 200 µM pefabloc) and phosphatase inhibitor (1 mM sodium
452 orthovanadate). Protein concentrations were analyzed using a BCA assay kit (Pierce).
453 Equal amounts of protein per lysate were separated by SDS-PAGE and transferred to a
454 nitrocellulose membrane. The membrane was blocked with tris-buffered saline (TBS)
455 supplemented with 0.1% (v/v) Tween 20 and 3% (w/v) BSA for one hour and incubated

456 with primary and HRP-linked secondary antibodies diluted in the blocking solution. In
457 some cases, TBS supplemented with 0.1% (v/v) Tween 20 and 5% (w/v) milk powder
458 was used (details for the used antibodies and conditions are listed in Table S2).
459 Detection was performed by a chemiluminescence reaction using the Fusion-FX7
460 Advance imaging system (Peqlab Biotechnologie GmbH).

461

462 *4.7 Energy depletion*

463 Energy depletion was carried out as described before (42). Briefly, MDCK cells were
464 washed 2 times with PBS supplemented with 100 mg/l CaCl₂ and 100 mg/l MgCl₂-
465 6H₂O (PBS++) and then treated with PBS++ supplemented with 10 mM 2-deoxy-D-
466 glucose and 10mM NaN₃ for 30 min at 37 °C.

467

468 *4.8 Bacteria culture and crawling experiments*

469 GFP-tagged *P. aeruginosa* PAO1 wild type (PAO1-wt) and LecB-deficient (PAO1-
470 dLecB) strains were provided by S. de Bentzmann (CNRS - Aix Marseille University,
471 France). The generation of LecB-deficient PAO1 is described in (23) and GFP-tagging
472 was carried out according to the procedure described in (57). For experiments, bacteria
473 were cultured overnight (approximately 16 h) in LB-Miller medium containing 60
474 µg/ml gentamicin in a shaker (Thriller, Peqlab) at 37 °C and 650 rpm. The bacteria
475 reached an OD measured at 600 nm of approximately 5. Using these growth conditions,
476 PAO1-wt and PAO1-dLecB strains showed comparable growth kinetics (Fig. S7A) and
477 harvested PAO1-wt efficiently expressed LecB, whereas PAO1-dLecB did not (Figs.
478 S7B and S7C).

479 For crawling experiments MDCK cells were sparsely seeded on 8 well Lab-Tek II
480 chambered cover glasses and cultured for 1 d, so that clusters with maximally 10 cells

481 in diameter formed to ensure that all cells were exposed to *P. aeruginosa* similar as at
482 a wound edge. Then, PAO1-wt or PAO-dLecB were applied for the indicated MOI and
483 duration. Bacteria crawling under cells were counted manually per cell from confocal
484 image stacks of whole cells to ensure that only bacteria located directly underneath cells
485 at the level of the glass cover slip were counted.

486

487 *4.9 qPCR*

488 PAO1-wt and PAO1-dLecB were cultured overnight as described before. RNA was
489 extracted using TRI reagent (Sigma Aldrich). After DNase digest, 100 ng RNA was
490 transcribed into cDNA using a first strand cDNA synthesis kit (Thermo Fisher). Then
491 qPCR was performed on a CFX384 qPCR cycler (Bio-Rad) using a SYBR Select
492 master mix (Thermo Fisher) and the following primers: for LecB: forward: 3'-
493 AAGGAGTGTTACCCTTCCC-5', reverse: 3'-GATGACGGCGTTATTGGTGC-
494 5'; for rpoD as reference: forward: 3'-GGGATACCTGACTTACGCGG-5', reverse:
495 3'-GGGGCTGTCTCGAATACGTT-5'.

496

497 *4.10 Labeling of lectins*

498 LecB was labeled with fluorescent dyes bearing NHS esters as reactive groups (Cy3
499 mono-reactive NHS ester (GE Healthcare), Cy5 mono-reactive NHS ester (GE
500 Healthcare), Alexa488 NHS ester (Thermo Fisher)) or with biotin using NHS-PEG12-
501 biotin (Thermo Fisher) according to the instructions of the manufacturers and purified
502 using PD-10 desalting columns (GE Healthcare).

503

504 *4.11 Cell surface biotinylation and immunoprecipitation*

505 For cell surface biotinylation, all following steps were carried out in a cold room (4 °C).
506 Sulfo-NHS-biotin (Thermo Fisher) was freshly diluted in PBS++ (concentration 0.3
507 mg/ml) and applied to the apical or basolateral plasma membrane of transwell filter
508 grown MDCK cells for 20 min. Afterwards, the reaction was quenched for 20 min with
509 PBS++ supplemented with 50 mM ammonium chloride. Cells were lysed with RIPA
510 buffer and biotinylated proteins were precipitated with streptavidin-agarose beads
511 (Thermo Fisher). Elution was carried out with Laemmli buffer (2% (w/v) SDS, 10%
512 (v/v) glycerol, 60 mM Tris-Cl (pH 6.8) in water) and boiling at 98 °C for 5 min.

513 For β 1-integrin IP, MDCK cells were grown to confluence in 10 cm dishes and lysed
514 in IP lysis buffer (50 mM Tris-HCl (pH 7.5), 150 mM sodium chloride, 1% (v/v)
515 IGEPAL CA-630, 0.5% (w/v) sodium deoxycholate in water). The lysates were pre-
516 cleared with protein A-agarose beads (Roche) for 3 h and then incubated with anti- β 1-
517 integrin antibodies (MAB2000 from Millipore) for 1 h. After adding of protein A-
518 agarose beads overnight, beads were washed three times with IP-lysis buffer, and β 1-
519 integrin was eluted with Laemmli buffer and boiling at 98 °C for 5 min.

520

521 *4.12 Mass spectrometry-based identification of LecB interaction partners*

522 MDCK cells were cultured in SILAC media for 9 passages and then seeded on transwell
523 filters and allowed to polarize for 4 d. For the first sample, biotinylated LecB was
524 applied to the apical side of light-SILAC-labeled cells and on the basolateral side of
525 medium-SILAC-labeled cells, whereas heavy-SILAC-labeled cells received no
526 stimulation and served as control. For the second sample, the treatment conditions were
527 permuted. After lysis with IP lysis buffer, the different SILAC lysates were combined
528 and LecB-biotin-receptor complexes were precipitated using streptavidin agarose beads
529 as described before. Eluted LecB-biotin-receptor complexes were then prepared for MS

530 analysis using SDS-PAGE gel electrophoresis. Gels were cut into pieces, proteins
531 therein digested with trypsin and resulting peptides were purified by STAGE tips.
532 For mass spectrometry analysis, samples were fractionated by nanoscale HPLC on a
533 1200 HPLC (Agilent Technologies, Waldbronn, Germany) connected online to a LTQ
534 Orbitrap XL mass spectrometer (Thermo Fisher Scientific, Bremen, Germany). Fused
535 silica HPLC-column tips with 75 μm inner diameter were self-packed with Reprosil-
536 Pur 120 ODS-3 (Dr. Maisch, Ammerbuch, Germany) to a length of 20 cm. Samples
537 were directly injected into the mass spectrometer. For details see reference #(58). The
538 raw data files were uploaded into the MaxQuant software. Database searches were
539 performed against a full-length dog database containing common contaminants such as
540 keratins and enzymes used for in-gel digestion. Carbamidomethylcysteine was set as
541 fixed modification, oxidation of methionine and protein amino-terminal acetylation
542 was set as variable modifications. Triple SILAC was used as quantitation mode. The
543 enzyme specificity was trypsin/P+DP with three allowed miss cleavages. The MS/MS
544 tolerance was set to 0.5 Da and the mass precision of identified peptides after
545 recalibration was in general less than 1 ppm. For identification and quantitation, the
546 following settings were used: peptide and protein FDR were set to 0.01, maximum
547 peptide posterior error probability (PEP) was set to 0.1, minimum peptide length was
548 set to 7, minimum number peptides for identification and quantitation of proteins was
549 set to two of which one must be unique, minimum ratio count was set to two, and only
550 unmodified peptides and the variable modification were used for protein quantification.
551 The “match between run” option was used with a time window of 2 min.
552 From the generated list of MS-identified proteins we defined those proteins as LecB
553 interaction partners that showed more than 2-fold enrichment on a log₂-scale over
554 controls in both SILAC samples (see Table S1).

555

556 *4.13 GUV experiments*

557 Giant unilamellar vesicles (GUVs) were composed of DOPC, spiked with 1 mol%
558 BODIPY-FL-C₅-HPC, 30 mol% cholesterol, and 5 mol% of the desired
559 glycosphingolipid species. Blood group glycosphingolipids were provided by Göran
560 Larson (Sahlgrenska University Hospital, Gothenburg, Sweden). GUVs were grown at
561 room temperature using the electroformation technique on indium-tin oxide (ITO)-
562 coated slides as described previously (42, 43). Briefly, lipid mixtures were dissolved in
563 chloroform at a final concentration of 0.5 mg/ml, and 15 µl solution was spread on the
564 conductive surface of ITO slides. After 2 h of drying under vacuum, GUVs were grown
565 in a 290 mosM sucrose solution by applying an alternating electric field from 20 mV
566 to 1.1 V for 3 h.

567 LecB-Cy3 (15 µg/ml) was incubated with GUVs at room temperature and examined
568 under an inverted confocal fluorescence microscope (Nikon A1R) equipped with an oil
569 immersion objective (60x, NA 1.49).

570

571 *4.14 Statistics*

572 If not stated otherwise data obtained from n = 3 independent experiments were used to
573 calculate arithmetic means. Error bars represent standard error mean (SEM). Statistical
574 significance analysis was carried out using GraphPad Prism 5.

575

576 **5 Acknowledgements**

577 This work was supported by a German Research Foundation grant [RO 4341/2-1], the
578 Excellence Initiative of the German Research Foundation [EXC 294], the Ministry of
579 Science, Research and the Arts of Baden-Württemberg [Az: 33-7532.20], and a starting
580 grant from the European Research Council [Programme “Ideas,” ERC-2011-StG
581 282105]. R.T. acknowledges support from the Ministry of Science, Research and the
582 Arts of Baden-Württemberg [Az: 7533-30-10/25/36].

583 **6 References**

- 584 1. Lyczak JB, Cannon CL, Pier GB. 2002. Lung infections associated with cystic
585 fibrosis. *Clin Microbiol Rev* 15:194–222.
- 586 2. Franzetti F, Grassini A, Piazza M, Degl’Innocenti M, Bandera A, Gazzola L,
587 Marchetti G, Gori A. 2006. Nosocomial bacterial pneumonia in HIV-infected
588 patients: risk factors for adverse outcome and implications for rational empiric
589 antibiotic therapy. *Infection* 34:9–16.
- 590 3. Markou P, Apidianakis Y. 2014. Pathogenesis of intestinal *Pseudomonas*
591 *aeruginosa* infection in patients with cancer. *Front Cell Infect Microbiol* 3:115.
- 592 4. Barbier F, Andremont A, Wolff M, Bouadma L. 2013. Hospital-acquired
593 pneumonia and ventilator-associated pneumonia: recent advances in
594 epidemiology and management. *Curr Opin Pulm Med* 19:216–228.
- 595 5. Azzopardi EA, Azzopardi E, Camilleri L, Villapalos J, Boyce DE, Dziewulski
596 P, Dickson WA, Whitaker IS. 2014. Gram negative wound infection in
597 hospitalised adult burn patients-systematic review and metanalysis. *PLoS One*
598 9:e95042.
- 599 6. Stover C, Pham X, Erwin A, Mizoguchi S, Warrener P, Hickey M, Brinkman
600 F, Hufnagle W, Kowalik D, Lagrou M, Garber R, Goltry L, Tolentino E,
601 Westbrook-Wadman S, Yuan Y, Brody L, Coulter S, Folger K, Kas A, Larbig
602 K, Lim R, Smith K, Spencer D, Wong G, Wu Z, Paulsen I, Reizer J, Saier M,
603 Hancock R, Lory S, Olson M. 2000. Complete genome sequence of
604 *Pseudomonas aeruginosa* PAO1, an opportunistic pathogen. *Nature* 406:959–
605 964.
- 606 7. Maillet M, Pelloux I, Forli A, Vancoetsem K, Cheong Sing JS, Marfaing S,
607 Ducki S, Batailler P, Mallaret M-R. 2014. Nosocomial transmission of

- 608 carbapenem-resistant *Pseudomonas aeruginosa* among burn patients. *Infect*
609 *Control Hosp Epidemiol* 35:597–599.
- 610 8. Kinsey CB, Koirala S, Solomon B, Rosenberg J, Robinson BF, Neri A, Halpin
611 AL, Arduino MJ, Moulton-Meissner H, Noble-Wang J, others. 2017.
612 *Pseudomonas aeruginosa* Outbreak in a Neonatal Intensive Care Unit
613 Attributed to Hospital Tap Water. *Infect Control Hosp Epidemiol* 38:801–808.
- 614 9. Mah T-F, Pitts B, Pellock B, Walker GC, Stewart PS, O’Toole GA. 2003. A
615 genetic basis for *Pseudomonas aeruginosa* biofilm antibiotic resistance. *Nature*
616 426:306.
- 617 10. Engel J, Eran Y. 2011. Subversion of mucosal barrier polarity by *Pseudomonas*
618 *aeruginosa*. *Front Microbiol* 2:1–7.
- 619 11. WHO. 2017. WHO priority pathogens list for research and development of new
620 antibiotics.
- 621 12. Wagner S, Sommer R, Hinsberger S, Lu C, Hartmann RW, Empting M, Titz A.
622 2016. Novel Strategies for the Treatment of *Pseudomonas aeruginosa*
623 Infections. *J Med Chem* 59:5929–5969.
- 624 13. Golovkine G, Faudry E, Bouillot S, Elsen S, Attrée I, Huber P. 2016.
625 *Pseudomonas aeruginosa* transmigrates at epithelial cell-cell junctions,
626 exploiting sites of cell division and senescent cell extrusion. *PLoS Pathog*
627 12:e1005377.
- 628 14. Tran CS, Eran Y, Ruch TR, Bryant DM, Datta A, Brakeman P, Kierbel A,
629 Wittmann T, Metzger RJ, Mostov KE, Engel JN. 2014. Host cell polarity
630 proteins participate in innate immunity to *Pseudomonas aeruginosa* infection.
631 *Cell Host Microbe* 15:636–43.
- 632 15. Kwok T, Zabler D, Urman S, Rohde M, Hartig R, Wessler S, Misselwitz R,

- 633 Berger J, Sewald N, Konig W, Backert S. 2007. Helicobacter exploits integrin
634 for type IV secretion and kinase activation. *Nature* 449:862–866.
- 635 16. Stewart PL, Nemerow GR. 2007. Cell integrins: commonly used receptors for
636 diverse viral pathogens. *Trends Microbiol* 15:500–507.
- 637 17. Cossart P. 1997. Host/pathogen interactions. Subversion of the mammalian cell
638 cytoskeleton by invasive bacteria. *J Clin Invest* 99:2307–2311.
- 639 18. Roger P, Puchelle E, Bajolet-Laudinat O, Tournier J-M, Debordeaux C,
640 Plotkowski M-C, Cohen JHM, Sheppard D, De Bentzmann S. 1999.
641 Fibronectin and $\alpha 5 \beta 1$ integrin mediate binding of *Pseudomonas aeruginosa* to
642 repairing airway epithelium. *Eur Respir J* 13:1301–1309.
- 643 19. Leroy-Dudal J, Gagnière H, Cossard E, Carreiras F, Di Martino P. 2004. Role
644 of $\alpha \nu \beta 5$ integrins and vitronectin in *Pseudomonas aeruginosa* PAK interaction
645 with A549 respiratory cells. *Microbes Infect* 6:875–881.
- 646 20. Imberty A, Wimmerová M, Mitchell EP, Gilboa-Garber N. 2004. Structures of
647 the lectins from *Pseudomonas aeruginosa*: Insights into the molecular basis for
648 host glycan recognition. *Microbes Infect* 6:221–228.
- 649 21. Tielker D, Hacker S, Loris R, Strathmann M, Wingender J, Wilhelm S,
650 Rosenau F, Jaeger KE. 2005. *Pseudomonas aeruginosa* lectin LecB is located
651 in the outer membrane and is involved in biofilm formation. *Microbiology*
652 151:1313–1323.
- 653 22. Funken H, Bartels KM, Wilhelm S, Brocker M, Bott M, Bains M, Hancock
654 REW, Rosenau F, Jaeger KE. 2012. Specific Association of Lectin LecB with
655 the Surface of *Pseudomonas aeruginosa*: Role of Outer Membrane Protein
656 OprF. *PLoS One* 7:1–8.
- 657 23. Chemani C, Imberty A, De Bentzmann S, Pierre M, Wimmerová M, Guery BP,

- 658 Faure K. 2009. Role of LecA and LecB lectins in *Pseudomonas aeruginosa*-
659 induced lung injury and effect of carbohydrate ligands. *Infect Immun* 77:2065–
660 2075.
- 661 24. Adam EC, Mitchell BS, Schumacher DU, Grant G, Schumacher U. 1997.
662 *Pseudomonas aeruginosa* II lectin stops human ciliary beating: Therapeutic
663 implications of fucose. *Am J Respir Crit Care Med* 155:2102–2104.
- 664 25. Cott C, Thuenauer R, Landi A, Kühn K, Juillot S, Imberty A, Madl J, Eierhoff
665 T, Römer W. 2016. *Pseudomonas aeruginosa* lectin LecB inhibits tissue repair
666 processes by triggering β -catenin degradation. *Biochim Biophys Acta (BBA)-*
667 *Molecular Cell Res* 1863:1106–1118.
- 668 26. Sommer R, Wagner S, Rox K, Varrot A, Hauck D, Wamhoff E-C, Schreiber J,
669 Ryckmans T, Brunner T, Rademacher C, others. 2018. Glycomimetic, orally
670 bioavailable LecB inhibitors block biofilm formation of *Pseudomonas*
671 *aeruginosa*. *J Am Chem Soc* 140:2537–2545.
- 672 27. Sommer R, Hauck D, Varrot A, Wagner S, Audfray A, Prestel A, Möller HM,
673 Imberty A, Titz A. 2015. Cinnamide Derivatives of d-Mannose as Inhibitors of
674 the Bacterial Virulence Factor LecB from *Pseudomonas aeruginosa*.
675 *ChemistryOpen* 4:756–767.
- 676 28. Johansson EM V, Crusz SA, Kolomiets E, Buts L, Kadam RU, Cacciarini M,
677 Bartels K-M, Diggle SP, Cámara M, Williams P, others. 2008. Inhibition and
678 dispersion of *Pseudomonas aeruginosa* biofilms by glycopeptide dendrimers
679 targeting the fucose-specific lectin LecB. *Chem Biol* 15:1249–1257.
- 680 29. Donnier-Marechal M, Abdullayev S, Bauduin M, Pascal Y, Fu M-Q, He X-P,
681 Gillon E, Imberty A, Kipnis E, Dessein R, Vidal S. 2018. Tetraphenylethylene-
682 based glycoclusters with aggregation-induced emission (AIE) properties as

- 683 high-affinity ligands of bacterial lectins. *Org Biomol Chem* 16:8804–8809.
- 684 30. Bucher KS, Babic N, Freichel T, Kovacic F, Hartmann L. 2018. Monodisperse
685 Sequence-Controlled alpha-l-Fucosylated Glycooligomers and Their
686 Multivalent Inhibitory Effects on LecB. *Macromol Biosci* e1800337.
- 687 31. Dupin L, Noel M, Bonnet S, Meyer A, Gehin T, Bastide L, Randriantsoa M,
688 Souteyrand E, Cottin C, Vergoten G, Vasseur J-J, Morvan F, Chevolut Y,
689 Darblade B. 2018. Screening of a library of oligosaccharides targeting lectin
690 LecB of *Pseudomonas aeruginosa* and synthesis of high affinity
691 oligoglycoclusters. *Molecules* 23.
- 692 32. Rodriguez-Boulan E, Kreitzer G, Müsch A. 2005. Organization of vesicular
693 trafficking in epithelia. *Nat Rev Mol Cell Biol* 6:233–247.
- 694 33. Thuenauer R, Hsu YC, Carvajal-Gonzalez JM, Deborde S, Chuang J, Römer
695 W, Sonnleitner A, Rodriguez-Boulan E, Sung C. 2014. Four-dimensional live
696 imaging of apical biosynthetic trafficking reveals a post-Golgi sorting role of
697 apical endosomal intermediates. *Proc Natl Acad Sci U S A* 111:4127–32.
- 698 34. Kierbel A, Gassama-Diagne A, Rocha C, Radoshevich L, Olson J, Mostov K,
699 Engel J. 2007. *Pseudomonas aeruginosa* exploits a PIP3-dependent pathway to
700 transform apical into basolateral membrane. *J Cell Biol* 177:21–27.
- 701 35. Audette GF, Vandonselaar M, Delbaere LTJ. 2000. The 2.2 Å resolution
702 structure of the O (H) blood-group-specific lectin I from *Ulex europaeus*. *J Mol*
703 *Biol* 304:423–433.
- 704 36. Myllymäki SM, Teräväinen TP, Manninen A. 2011. Two distinct integrin-
705 mediated mechanisms contribute to apical lumen formation in Epithelial cells.
706 *PLoS One* 6.
- 707 37. Greciano PG, Moyano J V, Buschmann MM, Tang J, Lu Y, Rudnicki J,


- 708 Manninen A, Matlin KS. 2012. Laminin 511 partners with laminin 332 to
709 mediate directional migration of Madin-Darby canine kidney epithelial cells.
710 *Mol Biol Cell* 23:121–136.
- 711 38. Le Bivic A, Sambuy Y, Mostov K, Rodriguez-Boulan E. 1990. Vectorial
712 targeting of an endogenous apical membrane sialoglycoprotein and uvomorulin
713 in MDCK cells. *J Cell Biol* 110:1533–1539.
- 714 39. Furtak V, Hatcher F, Ochieng J. 2001. Galectin-3 mediates the endocytosis of
715 β -1 integrins by breast carcinoma cells. *Biochem Biophys Res Commun*
716 289:845–850.
- 717 40. Lakshminarayan R, Wunder C, Becken U, Howes MT, Benzing C, Arumugam
718 S, Sales S, Ariotti N, Chambon V, Lamaze C, others. 2014. Galectin-3 drives
719 glycosphingolipid-dependent biogenesis of clathrin-independent carriers. *Nat*
720 *Cell Biol* 16:592.
- 721 41. Mitchell EP, Sabin C, Šnajdrová L, Pokorná M, Perret S, Gautier C, Hofr C,
722 Gilboa-Garber N, Koča J, Wimmerová M, Imberty A. 2005. High affinity
723 fucose binding of *Pseudomonas aeruginosa* lectin PA-IIL: 1.0 Å resolution
724 crystal structure of the complex combined with thermodynamics and
725 computational chemistry approaches. *Proteins Struct Funct Genet* 58:735–746.
- 726 42. Römer W, Berland L, Chambon V, Gaus K, Windschiegl B, Tenza D, Aly
727 MRE, Fraisier V, Florent J-C, Perrais D, Lamaze C, Raposo G, Steinem C,
728 Sens P, Bassereau P, Johannes L. 2007. Shiga toxin induces tubular membrane
729 invaginations for its uptake into cells. *Nature* 450:670–675.
- 730 43. Römer W, Pontani LL, Sorre B, Rentero C, Berland L, Chambon V, Lamaze C,
731 Bassereau P, Sykes C, Gaus K, Johannes L. 2010. Actin Dynamics Drive
732 Membrane Reorganization and Scission in Clathrin-Independent Endocytosis.

- 733 Cell 140:540–553.
- 734 44. Wood S, Sivaramakrishnan G, Engel J, Shafikhani SH. 2011. Cell migration
735 regulates the kinetics of cytokinesis. *Cell Cycle* 10:648–654.
- 736 45. Thuenauer R, Nicklaus S, Frensch M, Troendle K, Madl J, Römer W. 2018. A
737 microfluidic biochip for locally confined stimulation of cells within an
738 epithelial monolayer. *RSC Adv* 8:7839–7846.
- 739 46. Baldus SE, Thiele J, Park Y-O, Hanisch F-G, Bara J, Fischer R. 1996.
740 Characterization of the binding specificity of *Anguilla anguilla* agglutinin
741 (AAA) in comparison to *Ulex europaeus* agglutinin I (UEA-I). *Glycoconj J*
742 13:585–590.
- 743 47. Sughii S, Kabat E, HH B. 1982. Further immunochemical studies on the
744 combining sites of *Lotus tetragonolobus* and *Ulex europaeus* I and II lectins.
745 *Carbohydr Res* 99:99–101.
- 746 48. Marotte K, Sabin C, Prville C, Moumé-Pymbock M, Wimmerová M, Mitchell
747 EP, Imberty A, Roy R. 2007. X-ray structures and thermodynamics of the
748 interaction of PA-IIL from *Pseudomonas aeruginosa* with disaccharide
749 derivatives. *ChemMedChem* 2:1328–1338.
- 750 49. Perret S, Sabin C, Dumon C, Pokorná M, Gautier C, Galanina O, Ilia S, Bovin
751 N, Nicaise M, Desmadril M, others. 2005. Structural basis for the interaction
752 between human milk oligosaccharides and the bacterial lectin PA-IIL of
753 *Pseudomonas aeruginosa*. *Biochem J* 389:325–332.
- 754 50. Mitchell E, Houles C, Sudakevitz D, Wimmerova M, Gautier C, Pérez S, Wu
755 AM, Gilboa-Garber N, Imberty A. 2002. Structural basis for oligosaccharide-
756 mediated adhesion of *Pseudomonas aeruginosa* in the lungs of cystic fibrosis
757 patients. *Nat Struct Mol Biol* 9:918.

- 758 51. Boukerb AM, Decor A, Ribun S, Tabaroni R, Rousset A, Commin L, Buff S,
759 Doleans-Jordheim A, Vidal S, Varrot A, Imberty A, Cournoyer B. 2016.
760 Genomic Rearrangements and Functional Diversification of lecA and lecB
761 Lectin-Coding Regions Impacting the Efficacy of Glycomimetics Directed
762 against *Pseudomonas aeruginosa*. *Front Microbiol* 7:811.
- 763 52. Sommer R, Wagner S, Varrot A, Nycholat CM, Khaledi A, Haussler S,
764 Paulson JC, Imberty A, Titz A. 2016. The virulence factor LecB varies in
765 clinical isolates: consequences for ligand binding and drug discovery. *Chem*
766 *Sci* 7:4990–5001.
- 767 53. Villringer S, Madl J, Sych T, Manner C, Imberty A, Römer W. 2018. Lectin-
768 mediated protocell crosslinking to mimic cell-cell junctions and adhesion. *Sci*
769 *Rep* 8:1932.
- 770 54. Ewers H, Römer W, Smith AE, Bacia K, Dmitrieff S, Chai W, Mancini R,
771 Kartenbeck J, Chambon V, Berland L, Oppenheim A, Schwarzmann G, Feizi
772 T, Schwille P, Sens P, Helenius A, Johannes L. 2010. GM1 structure
773 determines SV40-induced membrane invagination and infection. *Nat Cell Biol*
774 12:11–18; sup pp 1-12.
- 775 55. Arnaud J, Tröndle K, Claudinon J, Audfray A, Varrot A, Römer W, Imberty A.
776 2014. Membrane deformation by neolectins with engineered glycolipid binding
777 sites. *Angew Chemie - Int Ed* 53:9267–9270.
- 778 56. Thuenauer R, Juhasz K, Mayr R, Frühwirth T, Lipp A-M, Balogi Z,
779 Sonnleitner A. 2011. A PDMS-based biochip with integrated sub-micrometre
780 position control for TIRF microscopy of the apical cell membrane. *Lab Chip*
781 11:3064–3071.
- 782 57. Eierhoff T, Bastian B, Thuenauer R, Madl J, Audfray A, Aigal S, Juillot S,

783 Rydell GE, Müller S, de Bentzmann S, Imberty A, Fleck C, Römer W. 2014. A
784 lipid zipper triggers bacterial invasion. *Proc Natl Acad Sci U S A* 111:6–11.
785 58. Thriene K, Gruning BA, Bornert O, Erxleben A, Leppert J, Athanasiou I,
786 Weber E, Kiritsi D, Nystrom A, Reinheckel T, Backofen R, Has C, Bruckner-
787 Tuderman L, Dengjel J. 2018. Combinatorial Omics Analysis Reveals
788 Perturbed Lysosomal Homeostasis in Collagen VII-deficient Keratinocytes.
789 *Mol Cell Proteomics* 17:565–579.
790

791 **7 Figures and Figure Legends**




792

793 **Fig. 1: Basolateral LecB application depolarized MDCK cells and caused integrin**
794 **internalization**

795 (A) Polarized, filter-grown MDCK cells stably expressing the apical marker GPI-GFP
796 (green) were left untreated (ctrl) or treated apically (AP) or basolaterally (BL) with 50
797 $\mu\text{g/ml}$ LecB for the indicated time periods, fixed and stained with antibodies
798 recognizing the basolateral marker β -catenin (red) and the tight junction marker ZO-1
799 (white), nuclei were stained with DAPI (blue). Representative sections along the apico-
800 basal axis (x-z sections) extracted from confocal image stacks are shown. (B) Time
801 course of the trans-epithelial electrical resistance (TEER) of MDCK monolayers treated
802 AP or BL with LecB. The mean values from $n = 3$ experiments are displayed. (C) LecB

803 was applied BL to MDCK cells stably expressing PH-Akt-GFP (green) for the indicated
804 time periods. Cells were fixed and stained for β 1-integrin (red); nuclei were stained
805 with DAPI (blue). Representative x-z sections extracted from confocal image stacks are
806 depicted. (D) MDCK cells were treated with LecB as indicated, fixed, and stained for
807 β 1-integrin (red) and β -catenin (green). Maximum intensity projections of confocal
808 image stacks covering total cell heights are shown. (E) The time course of the TEER of
809 MDCK cells treated BL with LecB as indicated and after washout was measured.



827

828 **Figure 3: LecB internalizes $\alpha 3\beta 1$ -integrin regardless of its activation status and**

829 **together with laminins**

830 (A) MDCK cells were treated with LecB as indicated, fixed with methanol, and stained

831 for $\alpha 3$ -integrin (red) and $\beta 1$ -integrin (green). Confocal sections (x-y sections) through

832 the middle of the cells extracted from confocal image stacks are shown. (B) MDCK

833 cells were treated with LecB-Cy3 (red) as indicated, fixed, and stained for pan-laminin

834 (green), and $\beta 1$ -integrin (magenta); nuclei were stained with DAPI (blue); x-y confocal


835 sections through the middle of the cells are depicted. (C) – (E) MDCK cells were treated

836 with LecB as indicated and surface biotinylation from the basolateral side was

837 performed. After precipitation of biotinylated proteins, the precipitates representing the

838 surface fraction (S) and the supernatant representing the intracellular fraction (I) were


839 subjected to Western blot analysis and $\alpha 3$ -integrins and $\beta 1$ -integrins were probed, as
840 well as actin to control for purity of the surface fractions. Quantification for $\alpha 3$ - (D)
841 and $\beta 1$ - (E) subunit-composed integrins from $n = 3$ independent experiments. (F) – (H)
842 LecB was applied basolaterally to MDCK cells for the indicated time periods followed
843 by basolateral application of activation-specific anti- $\beta 1$ -integrin antibodies to live cells.
844 After fixation, the signal from bound anti- $\beta 1$ -integrin antibodies in randomly chosen
845 regions of interest was measured and normalized to the cell number in the regions ($n =$
846 5 for one experiment). The graphs show the mean value from $n = 3$ experiments with
847 the activating anti- $\beta 1$ -integrin antibody 9EG7 (F), and the inhibitory anti- $\beta 1$ -integrin
848 antibodies mAB 13 (G) and AIIB2 (H).



849

850 **Figure 4: Mechanism of LecB-mediated integrin internalization via crosslinking**
851 **glycosphingolipids and integrins**


852 (A) LecB-Cy3 (15 μg/ml, red) was applied to GUVs containing fucosylated
853 glycosphingolipids bearing the Lewis a antigen (Lewis a) or the non-fucosylated
854 precursor lactotetraosylceramide (Lc4cer) and BODIPY-FL-C5-HPC (bodipy; green)
855 as a membrane marker. Confocal sections along equatorial planes of the GUVs are
856 displayed; white arrows point to membrane invaginations caused by LecB. (B) Sub-
857 confluent MDCK cells grown on glass cover slips were energy-depleted (e.d.) or left
858 untreated (no e.d.). LecB-Cy3 (red) was applied to the cells for 1 h, cells were fixed,
859 and stained for β1-integrin (green). Confocal x-y sections at the level of the cell
860 adhesion to the glass cover slip are displayed.



861

862 **Figure 5: LecB inhibits epithelial wound healing**

863 (A) – (C) Polarized monolayers of MDCK cells grown in 12 well plates were wounded
864 with a pipet tip and imaged with a wide field microscope at the indicated time points to
865 observe wound closure. In (A) cells were treated with LecB and/or L-fucose (43 mM)
866 to block LecB, whereas in (B) increasing concentrations of LecB were used. The
867 quantification of the migration speeds of the wound edges from the latter experiment
868 (C) shows that concentrations larger than 50 $\mu\text{g/ml}$ LecB completely inhibit wound
869 healing; n = 3. (D) Polarized monolayers of MDCK cells stably expressing the plasma
870 membrane marker ML-GFP (green) grown on chambered cover glasses were wounded
871 and left untreated (ctrl) or treated with LecB followed by live imaging of the wound
872 edge by confocal microscopy. Lamellipodia are indicated with white arrows. (E)
873 Polarized MDCK monolayers grown on chambered cover glasses were wounded and
874 treated with LecB-Alexa488 (green) for 3 h. Cells were fixed and stained for $\beta 1$ -integrin
875 (red). A x-y confocal section at half height of the cells is shown. White arrows point to
876 internalized $\beta 1$ -integrins co-localizing with LecB-Alexa488; the dashed line outlines
877 the wound edge.



878

879 **Figure 6: LecB promotes crawling of *P. aeruginosa* underneath cells**

880 (A) Sparsely seeded MDCK cells were incubated with GFP-tagged PAO1-wt or LecB-
881 deficient PAO1-dLecB (green) at an MOI of 50 for 1 h. After fixation, β 1-integrins
882 were stained in red. For each condition, a confocal x-y section at the level of cell
883 adhesion to the substrate, which was taken from a complete three-dimensional confocal
884 stack is displayed. White arrows indicate bacteria underneath cells. (B) – (D) After
885 carrying out an experiment as described in (A) but with indicated MOIs and incubation
886 periods, the numbers of bacteria underneath cells were determined per cell. Each data
887 point represents an individual cell and the black marks indicate the mean and the SEM.

888 For evaluating statistical significance, Mann-Whitney testing using GraphPad Prism 5

889 was applied, **** denotes $p < 0.0001$.